METHODS
The results of major clinical trials in cardiology presented at major conferences in 2015 were reviewed by the authors. Search terms included ''acute coronary syndrome'', ''atrial fibrillation'', ''coronary prevention'', ''electrophysiology'', ''heart failure'', and ''interventional cardiology''. Trials were selected based on relevance to the cardiovascular (CV) community, the potential to change clinical practice, and the potential to guide further phase 3 research. This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors.
HEART FAILURE
Advances in heart failure (HF) have featured prominently in many 2015 conferences with particular focus on addressing the side effects of currently used drug classes. Mineralocorticoid antagonists (MRAs) have a class 1A recommendation for reduction in mortality and hospitalization in patients with heart failure with reduced ejection fraction (EF).
However, this drug class is typically under-prescribed due to concerns regarding hyperkalemia and renal impairment in high-risk patients. Finerenone is a novel non-steroidal MRA with greater receptor selectivity than spironolactone and better receptor affinity than eplerenone in vitro [1, 2] , which may have the potential to reduce side effects of hyperkalemia and renal impairment [1] . The ARTS-HF
(mineralocorticoid Receptor antagonist
Tolerability Study-Heart Failure) double-blind controlled phase 2b trial (ClinicalTrials.gov #NCT01807221) randomized 1060 patients with heart failure (HF), type 2 diabetes mellitus (T2DM) ± chronic kidney disease (CKD) to finerenone (titrated from one of five doses from 2.5 to 20 mg) or eplerenone (titrating from 25 to 50 mg) [1, 2] . Although the proportion of patients with a relative decrease of 30% in 90-day NT-proBNP (primary endpoint) was similar in all groups, the measurement of NT-proBNP to predict clinical outcome is not well established, and the subgroup of patients receiving finerenone 10-20 mg showed a 44% reduction the secondary clinical composite endpoint of 90-day all-cause death, CV death, hospitalization, or emergency presentation for worsening chronic HF [1, 2] . Finerenone 10-20 mg appeared better tolerated than eplerenone with a smaller increase in potassium (0.119 vs. 0.262 mmol/l; p = 0.016) and lower incidence of estimated glomerular filtration rate (eGFR) decrease [40% (4.2% vs. 9.4%) [1, 2] . A phase 3 trial has been announced. Hyperkalemia is a common concern in HF patients using renin-angiotensin-aldosterone (RAAS) inhibitors [3] . In a previous trial, OPAL-HK (ClinicalTrials.gov #NCT01810939),
investigators showed a short-term sustained decrease in potassium in patients with HF taking the potassium binder patiromer with RAAS inhibitors [4] . The phase 2 AMETHYST DN trial (ClinicalTrials.gov #NCT01371747)
assigned 304 patients with CKD, hypertension (HTN), T2DM, serum potassium above 5 mEq/l and who were taking RAAS inhibitors to patiromer (starting dose stratified by baseline potassium) [5] . Patiromer reduced potassium within days and maintained levels \5 mEq/l in patients with HF (n = 105) or without HF (n = 199) for up to 1 year (p\0.001). In total, 74% of the HF subgroup completed the trial, 7%
withdrew consent, and a further 7% had adverse effects such as diarrhea, hypokalemia, and hypomagnesemia [5] . Further studies are planned to assess if improved control of hyperkalemia will translate into survival benefit [5] .
Renal dysfunction is another common issue with RAAS inhibitors. A combination of the neprilysin inhibitor sacubitril and the angiotensin receptor blocker valsartan (LCZ696) was previously shown to decrease the primary endpoint of CV death or HF hospitalization, CV death, and a reduction in all-cause mortality compared with enalapril in the 2014 PARADIGM-HF study (prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in HF) (ClinicalTrials.gov #NCT01035255) [3, 6] .
The renal tolerability of sacubitril/valsartan was presented at the ESC Congress 2015 [7] . Over a 48-month period, eGFR decreased by 0.14 ml/ min/1.73 m 2 in the enalapril group and 0.11 ml/min/1.73 m 2 in the sacubitril/valsartan groups, respectively (p = 0.001) [7] . Although, it should be noted that patients with an acute initial decline in eGFR were excluded from the PARADIGM-HF study [7] , CV death or HF hospitalization was reduced similarly in the CKD group (36% of the study population) compared to those without baseline CKD (HR 0.790 vs. 0.799; p = 0.90 for interaction), [7] suggesting a favorable cardiorenal profile [7] . [10] . Patients receiving candesartan had a significantly smaller decline in EF from baseline vs. placebo (0.8% vs. 2.6%; p = 0.026) [10] . No significant benefit was demonstrated for metoprolol [10] . Although small in size, this study suggests potential benefit from candesartan therapy in this patient group.
Previous studies have yielded conflicting conclusions regarding the mortality effect of digoxin among patients with congestive heart failure (CHF) [11, 12] . Madelaire et al. thus conducted an observational study using a Danish nationwide registry of patients discharged from hospital with both HF and atrial fibrillation (AF), excluding those receiving antiarrhythmic therapy (e.g., amiodarone), those who died within 30 days of discharge, and those not taking a vitamin-K antagonist, then matching the 8078 digoxin-treated patients with 8078 control patients, based on age, sex, comorbidities, CHA2DS2VASc score, medication, and heart-failure severity [13] . [13] . When death was considered as a competing risk, the collective incidences of readmission were similar at 64.9% in digoxin users and 64.4% in non-users [13] . The authors concluded that in digoxin-naive patients with AF, digoxin use was associated with a slightly reduced risk of death [13] .
A novel heart failure strategy may be attenuation of myocyte sodium overload by beta 3 agonists. In the Beta 3 Agonists Treatment in HF (BEAT-HF) trial (ClinicalTrials.gov #NCT01876433) [14, 15] , 70 patients with HF were randomized to the beta 3 agonist Mirabegron or placebo for 6 months [14, 15] . While Mirabegron was not associated with improvement in patients with a baseline EF [40% (mean difference 0.4%; 95% CI -3.5 to 3.8; p = 0.82) an exploratory analysis of patients with a baseline EF B40% noted a 5.5% increase in EF (95% CI 0.6-10.4; p\0.03) [14, 15] . Further studies are thus planned in patients with severe heart failure [15] .
Since some diabetes therapies including some thiazolidinediones and some DPP-4 inhibitors have been associated with an increased risk of HF events, new diabetes therapies require rigorous evaluation of CV safety. TECOS (Trial Evaluating Cardiovascular Outcomes with Sitagliptin) (ClinicalTrials.gov #NCT00790205) randomized 14,671 patients with diabetics and CV disease (history of major coronary artery disease, ischemic cerebrovascular disease, or atherosclerotic peripheral arterial disease) to sitagliptin vs.
placebo [16] . At 3 years, there was no difference in the primary endpoint of CV death, non-fatal MI, non-fatal stroke, or hospitalization for unstable angina for with sitagliptin vs. placebo (11.4% vs. 11.6%; p\0.001 for noninferiority) [16] , no difference in total HF hospitalization events (345 vs. 347 placebo; p = 0.996) [16, 17] 
ANTICOAGULATION FOR ATRIAL FIBRILLATION
Until recently, the absence of a specific reversal agent for non-vitamin K antagonist oral anticoagulants (NOACs) has been seen as a limitation. In late 2015, the first specific reversal agent-idarucizumab-was approved for reversal of the direct thrombin inhibitor dabigatran [27] . Approval was based on interim results of REVERSE-AD (ClinicalTrials.gov #NCT02104947) [28, 29] in 90 patients-51 with serious bleeding (group A) and 39 requiring an urgent procedure (group B). The anticoagulant effects of dabigatran were rapidly (within minutes) and completely reversed in 88 to 98% of the patients who had had elevated clotting times at baseline [29] . Unbound dabigatran concentration at 24 h remained below 20 ng/ml in 79% of patients. One thrombotic event occurred within 72 h of idarucizumab in a patient who had not received anticoagulant re-initiation [29] .
Factor Xa oral anticoagulants do not yet have an approved reversal agent but andexanet alfa-a recombinant engineered version of human factor Xa with the ability to bind factor Xa inhibitors-has been tested in healthy older (aged 50-75) volunteers receiving apixaban 5 mg twice daily or rivaroxaban 20 mg once daily [30] . In apixaban participants, andexanet alfa reduced anti-Xa activity by 94% (vs. 21% receiving placebo; p\0.001) and thrombin generation was fully restored in 100% (vs. 11% receiving placebo; p\0.001) within 2 to 5 min [30] . Among the rivaroxaban participants, andexanet alfa reduced anti-factor Xa activity by 92% (vs. 18% receiving placebo) and thrombin generation was fully restored in 96% (vs. 7% receiving placebo; p\0.001) [30] . These effects were sustained when andexanet was administered as a bolus plus an infusion [30] . A phase IIIb/IV trial is now recruiting patients with active bleeding, treated with andexanet.
Balancing antithrombotic efficacy with bleeding safety remains a clinical challenge.
REGULATE-PCI
(ClinicalTrials.gov #NCT01848106), randomized patients undergoing PCI to the novel anti IXa anticoagulant pegnivacogin (n = 1616) prior to PCI with administration of the specific reversal agent anivamersen at the end of the PCI, or to bivalirudin (n = 1616) (standard bolus, plus infusion for the duration of the PCI) [31] . The trial was halted early as 10/1605 (0.6%) patients had severe allergic reactions with the novel regimen (including one fatality) compared to one severe allergic reaction with bivalirudin and had higher rates of bleeding (p = 0.002) [31] .
However, the primary efficacy outcomes were similar between the two groups, thus suggesting that factor IXa could be a potential target if the allergy issues could be addressed [31] .
The Assessment of an Education and
Guidance Programme for Eliquis Adherence in Non-Valvular Atrial Fibrillation (AEGEAN) (ClinicalTrials.gov #NCT01884350) study assessed the impact of an educational program on adherence to apixaban for stroke prevention in AF [32] . Adherence and persistence were measured by an electronic monitoring device, with non-adherence defined as a 24-h period where two tablets were missed and non-persistence a 30-day period of discontinuation [32] . Adherence was 88.51% for standard care and 88.34% for the educational programme (p = 0.89) at week 24 [32] . Persistence at 24 weeks was 90.5% with standard care and 91.1% with an educational programme (p = 0.7) [32] . The authors concluded there was no additional value found so far with an educational programme in the first 6 months of treatment. Long-term adherence will be evaluated in a follow-up study [32] . [33] . Echocardiography rather than computed tomography (CT) was routinely used for pre-procedure measurements, and low TAVR placement was felt to contribute to conduction abnormalities [33] . Although underpowered, NOTION suggests TAVR may be a reasonable alternative to surgical intervention even in low-risk patients [33] .
STRUCTURAL INTERVENTION
Neurological defects can be an important complication of TAVR. DEFLECT 3 (ClinicalTrials.gov #NCT02070731) was a small (n = 85) randomized trial investigating the use of the TriGuard embolic deflecting device vs.
control in patients undergoing TAVR [34] .
Complete three-vessel cerebral coverage was achieved in 88.9% of patients assigned to TriGuard [34] patients with severe aortic stenosis or regurgitation, a previous surgical bioprosthetic aortic valve and high operative risk [35] .
Patients had to be suitable for 23-mm or 26-mm valve and patients with surgical valves \21 mm were excluded [35] . At 1 year, the primary endpoint of all-cause mortality was 13.4%, cardiac mortality was 8.9%, stroke rate was 3.7%, and rehospitalization rate was 11.8% [35] . Peri-procedural major bleeding occurred in 14.8% and acute kidney injury in 8.2% [35] . Significant clinical benefit compared with baseline was noted for NYHA status, 6-min walk test, and quality of life [35] . Although non-randomized and sizing issues restrict the applicable population, PARTNER II suggests SAPIEN XT is a potential alternative to
CoreValve for valve-in-valve procedures [35] . In contrast to aortic valve disease, conventional surgery remains the primary treatment for mitral regurgitation in most patients. The optimal surgical approach can be hotly debated. vs. guideline-directed therapy (n = 481) were presented at TCT 2015 [37] . PFO closure was not associated with significant reduction in all-cause strokes in the overall intention-to-treat analysis (18 vs. 24; p = 0.16) but was associated with a significant reduction in cryptogenic stroke (10 vs. 19; HR 0.46; p = 0.042) [37] . In patients \60 years, PFO closure was associated with a 52% reduction in all-cause stroke (p = 0.035) [37] and in those with atrial septal aneurysmal or substantial shunts, PFO closure was associated with a 75% reduction in all-cause stroke (p = 0.007) [37] .
There was no intra-procedure stroke, no device embolization, no device thrombosis, no device erosion, a very low rate of major vascular complications (0.9%) and device explants (0.4%) [37] . RESPECT thus supports PFO closure in selected patients.
ATHEROSCLEROSIS
Despite use of high-dose statin and ezetimibe, patients with elevated LDL cholesterol can remain at elevated CV risk. Proprotein convertase subtilisin-kexin type 9 (PCSK9) (Fig. 3) [38] .
In an open-label extension study of OSLER-1 (ClinicalTrials.gov #NCT01439880) and OSLER-2 (ClinicalTrials.gov #NCT01854918) patients were randomly assigned in a 2:1 ratio to receive the PCSK9 inhibitor evolocumab (140 mg every 2 weeks or 420 mg monthly) plus standard therapy (n = 2976) or standard therapy alone (n = 1487) [39] . A second PCSK9 inhibitor, alirocumab, was evaluated in the ODYSSEY LONG TERM study (ClinicalTrials.gov number #NCT01507831) in which 2341 patients with LDL cholesterol [1.8 mmol/l despite maximum tolerated statin were randomized in 2:1 ratio to alirocumab (150 mg) or placebo subcutaneous injection every 2 weeks for 78 weeks [40] . At week 24, LDL-C in the alirocumab group had dropped 62% more from baseline than with placebo (p\0.001); an effect that remained consistent over 78 weeks [40] with acute coronary syndrome (ACS) to varenicline or placebo [41] . The primary endpoint (self-reported cessation at 24 weeks confirmed by carbon monoxide testing) was achieved in 47.3% of those receiving varenicline vs. 32.5% receiving placebo (p = 0.012; number needed to treat 6.8) [41] .
At follow-up, continuous abstinence was reported in 35.8% vs. 25.8% (p = 0.081) and rates of C50% reduction in cigarettes were 67.4% vs. 55.6% (p = 0.05) [41] . There was no significant difference in adverse events except for a higher incidence of abnormal dreams with varenicline (15.2% vs. 4.6%) [41] .
Blood pressure targets were relaxed in most recent guidelines [42] . The Systolic Blood Pressure Intervention Trial (SPRINT) (ClinicalTrials.gov #NCT01206062) [43] randomized 9361 patients aged over 50 with systolic blood pressure C130 mmHg, increased CV risk, but without diabetes, to a target systolic Fig. 3 Catabolism of the LDL particle; the role of PCSK9 and antibody to PCSK9. a Intracellular cholesterol homeostasis is modulated by the LDLR pathway. The LDLR is a cell-surface glycoprotein that is synthesized in the ER and processed in the Golgi apparatus, and transported to the cell surface. The LDLR specifically binds ApoB in LDL particles. The resulting receptor-ligand complex is then internalized by endocytosis, which involves the LDLRAP1. PCSK9 binds the LDLR-LDL complex extracellularly and prevents it from dissociating within the vesicle, thus targeting the whole complex for degradation in the lysosomal compartment. [44] . Hyperkalemia occurred in seven (4.8%) amiloride patients compared to three (2.3%) in the combination group [44] . In summary, combination therapy appeared to be a favorable treatment option being neutral for glucose and potassium but with greater effects on blood pressure [44] .
Lower fasting glucose and HbA1c levels with ranolazine have been suggested by previous trials in the setting of coronary disease [45, 46] [47] . Thus, ranolazine may be of particular benefit in patients with coronary disease and diabetes.
BIOMARKERS IN ACS
The Biomarkers in Acute Cardiovascular Care (BACC) study (ClinicalTrials.gov #NCT02355457) investigated the different cut-off values for high-sensitivity troponin I and testing at 1 vs. 3 h for early detection of acute MI among 1045 patients presenting with acute ischemic-type chest pain of whom 184 were ultimately diagnosed with acute MI [48] . A cut-off of 6 ng/l was found to be optimal rather than a conventional 99th percentile value for the assay (27 ng/l) [48] . For rule-out MI, using 
ANTIPLATELET THERAPY
The optimal duration of dual antiplatelet therapy (DAPT) after stenting has been widely debated. The Dual AntiPlatelet Therapy (DAPT) study (ClinicalTrials.gov #NCT00977938) [50] . TIMI major bleeding rates were significantly (p\0.001) increased in both ticagrelor groups compared with placebo (2.60% standard dose ticagrelor, 2.30% reduced dose ticagrelor vs. 1.06% placebo) although the incidence of intracranial hemorrhage or fatal bleeding was similar in all three groups [50] . Dyspnea was significantly more frequent with ticagrelor (18.93% standard dose 15.84% low dose vs. 6.38% placebo). Standard dose compared with low dose ticagrelor led to numerically higher rates of discontinuation [50] .
The DAPT and PEGASUS trials suggest that patients at high ischemic risk but low bleeding risk are most likely to benefit from extended therapy A 'DAPT score' has been developed from the DAPT study dataset to help identify patients who may derive net benefit and this, or a similar strategy, is likely to be addressed in future ACS guidelines.
PERCUTANEOUS CORONARY INTERVENTION
The requirement for at least 3-6 months of DAPT has limited use of drug eluting stents (DES) in patients at high baseline risk of bleeding. The BioFreedom stainless-steel stent incorporates a novel microporous abluminal surface (Fig. 4) No-reflow following PCI may be associated with adverse cardiac outcomes and reduced myocardial salvage (the final infarct size indexed to the initial area at risk 
ARRHYTHMIA AND DEVICES
Requirement for creation of a subcutaneous pacemaker pocket and insertion of a transvenous lead in conventional pacing systems can be associated with important complications such as pocket hematoma or infection, pneumothorax, or hemothorax. The Micra Transcatheter Pacing System Study (ClinicalTrials.gov #NCT02004873) evaluated use of a leadless pacemaker (Fig. 6 ) implanted in the right ventricular apex via femoral vein implantation and secured by small tines in 725 patients (719 successfully implanted) [65] . The primary safety endpoint (freedom from system or procedure related major complications) was achieved in 96% and the primary efficacy endpoint (percentage of patients with low and stable pacing capture thresholds at 6 months) in 98.3%-both of which were higher than the minimum performance goals from conventional pacing historical control data [65] . Major complications, which were less common than in the historical control dataset, included cardiac perforation or effusion/tamponade (1.6%), groin site complication (0.7%), and pacing issues (0.3%) but no (0%) dislodgments [65] .
Another leadless pacemaker-the Nanostim LP (St. Jude Medical)-was evaluated among 300 patients in the LEADLESS II study (ClinicalTrials.gov #NCT02030418) [66] . The primary safety endpoint (6-month freedom from device-related serious adverse events) was met in 93.3% and primary efficacy endpoint (acceptable 6-month pacing threshold and sensing amplitude) was met in 90%-both also exceeding minimum performance goals from conventional pacing historical control data [66] . In total, 6.7% had serious adverse events (1.7% device dislodgement with percutaneous retrieval, 1.3% cardiac perforation and 1.3% pacing-threshold elevation requiring percutaneous retrieval and device replacement) [66] . patient-years, p = 0.01) [67] . There was no difference in major cardiac or cerebrovascular adverse events at 12 months but the study was not powered to show benefit in this respect.
Although the CTSN study did not find an advantage for the more complex biatrial maze over PVI, with a transcatheter approach, persistent AF may benefit more extensive ablation. The BELIEF trial (ClinicalTrials.gov #NCT01362738) randomized 173 patients with long-standing persistent AF undergoing pulmonary vein antrum and non-pulmonary vein trigger ablation to additional left atrial appendage (LAA) electrical isolation (n = 85) or no LAA isolation (n = 88) [68] . Those undergoing LAA electrical isolation had significantly higher freedom from AF at 1-year (56% vs. 28%; HR, 1.92; p = 0.001) [68] . There was no significant difference in secondary endpoints including mortality, stroke, or re-hospitalization [68] .
Anticoagulation strategy was assessed in the randomized ActiVe-controlled multi-cENTer A second large multicenter CTA study (The SCOT-HEART trial) has helped to define the clinical impact of CTA further. SCOT-HEART randomized 9849 patients with an initial clinical diagnosis of coronary heart disease (CHD) in 47% and angina due to CHD in 36% to usual care plus CTA at *6 weeks or to usual care alone (ClinicalTrials.gov #NCT01149590) [73] . Use of CTA reclassified diagnosis of CHD in 27% and angina in 23% (vs. 1% and 1%, respectively, with usual care p\0.0001) and led to a change in planned investigation in 15% (cancellation of 121 functional tests, cancellation of 29 invasive
angiograms, but scheduling of an additional 94 invasive angiograms, 88% of which showed obstructive disease requiring revascularization) [73] . At a median follow-up of 1.7 years, there was a 38% trend to reduction in fatal and non-fatal MI (26 vs. 42, HR 0.62, 95% CI 0.38-1.01; p = 0.0527) [73] . SCOT-HEART thus confirmed that CTA helps clarify diagnosis, enables more appropriate use of invasive angiography/intervention and may reduce the future risk of MI [73] .
CONCLUSIONS
In this paper, we have highlighted and 
